Literature DB >> 18854309

Characterization of an alternative splice variant of LKB1.

Fiona C Denison1, Natalie J Hiscock1, David Carling2, Angela Woods3.   

Abstract

LKB1 is an upstream activating kinase for the AMP-activated protein kinase (AMPK) and at least 12 other AMPK-related kinases. LKB1 therefore acts as a master kinase regulating the activity of a wide range of downstream kinases, which themselves have diverse physiological roles. Here we identify a second form of LKB1 generated by alternative splicing of the LKB1 gene. The two LKB1 proteins have different C-terminal sequences generating a 50-kDa form (termed LKB1L) and a 48-kDa form (LKB1S). LKB1L is widely expressed in mouse tissues, whereas LKB1S has a restricted tissue distribution with predominant expression in the testis. LKB1S, like LKB1L, forms a complex with MO25 and STRAD, and phosphorylates and activates AMPK both in vitro and in intact cells. A phosphorylation site (serine 431 in mouse) and a farnesylation site (cysteine 433 in mouse) within LKB1L are not conserved in LKB1S raising the possibility that these sites might be involved in differential regulation and/or localization of the two forms of LKB1. However, we show that phosphorylation of serine 431 has no effect on LKB1L activity and that both LKB1L and LKB1S have similar patterns of subcellular localization. These results indicate that the physiological significance of the different forms of LKB1 is not related directly to differences in the C-terminal sequences but may be due to their differential patterns of tissue distribution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854309     DOI: 10.1074/jbc.M806153200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  The LKB1 complex-AMPK pathway: the tree that hides the forest.

Authors:  Michaël Sebbagh; Sylviane Olschwang; Marie-Josée Santoni; Jean-Paul Borg
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 2.  Role of the energy sensor AMP-activated protein kinase in renal physiology and disease.

Authors:  Kenneth R Hallows; Peter F Mount; Núria M Pastor-Soler; David A Power
Journal:  Am J Physiol Renal Physiol       Date:  2010-02-24

3.  The double edge of the HSP90-CDC37 chaperone machinery: opposing determinants of kinase stability and activity.

Authors:  Wanping Xu; Len Neckers
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

4.  Metabolic Control over mTOR-Dependent Diapause-like State.

Authors:  Abdiasis M Hussein; Yuliang Wang; Julie Mathieu; Lilyana Margaretha; Chaozhong Song; Daniel C Jones; Christopher Cavanaugh; Jason W Miklas; Elisabeth Mahen; Megan R Showalter; Walter L Ruzzo; Oliver Fiehn; Carol B Ware; C Anthony Blau; Hannele Ruohola-Baker
Journal:  Dev Cell       Date:  2020-01-27       Impact factor: 12.270

Review 5.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

6.  Phosphorylation of serine 399 in LKB1 protein short form by protein kinase Cζ is required for its nucleocytoplasmic transport and consequent AMP-activated protein kinase (AMPK) activation.

Authors:  Huaiping Zhu; Cate M Moriasi; Miao Zhang; Yu Zhao; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

7.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Post-translational modification of serine/threonine kinase LKB1 via Adduction of the Reactive Lipid Species 4-Hydroxy-trans-2-nonenal (HNE) at lysine residue 97 directly inhibits kinase activity.

Authors:  Timothy D Calamaras; Charlie Lee; Fan Lan; Yasuo Ido; Deborah A Siwik; Wilson S Colucci
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

9.  Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis.

Authors:  Zhonglin Xie; Yunzhou Dong; Junhua Zhang; Roland Scholz; Dietbert Neumann; Ming-Hui Zou
Journal:  Mol Cell Biol       Date:  2009-05-04       Impact factor: 4.272

10.  Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

Authors:  Matthew J Martin; Robert Hayward; Amaya Viros; Richard Marais
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.